ATE514714T1 - Hutnfr1-selektive antagonisten - Google Patents

Hutnfr1-selektive antagonisten

Info

Publication number
ATE514714T1
ATE514714T1 AT07005603T AT07005603T ATE514714T1 AT E514714 T1 ATE514714 T1 AT E514714T1 AT 07005603 T AT07005603 T AT 07005603T AT 07005603 T AT07005603 T AT 07005603T AT E514714 T1 ATE514714 T1 AT E514714T1
Authority
AT
Austria
Prior art keywords
hutnfr1
ligand
amino acid
acid sequences
selective antagonists
Prior art date
Application number
AT07005603T
Other languages
English (en)
Inventor
Klaus Pfizenmaier
Peter Scheurich
Roland Kontermann
Sabine Muenkel
Original Assignee
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart filed Critical Univ Stuttgart
Application granted granted Critical
Publication of ATE514714T1 publication Critical patent/ATE514714T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
AT07005603T 2007-03-19 2007-03-19 Hutnfr1-selektive antagonisten ATE514714T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07005603A EP1972637B1 (de) 2007-03-19 2007-03-19 huTNFR1-selektive Antagonisten

Publications (1)

Publication Number Publication Date
ATE514714T1 true ATE514714T1 (de) 2011-07-15

Family

ID=38358021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07005603T ATE514714T1 (de) 2007-03-19 2007-03-19 Hutnfr1-selektive antagonisten

Country Status (9)

Country Link
US (2) US8404238B2 (de)
EP (2) EP1972637B1 (de)
JP (1) JP5534819B2 (de)
CN (1) CN101679520B (de)
AT (1) ATE514714T1 (de)
CA (1) CA2680085C (de)
ES (1) ES2368764T3 (de)
PL (1) PL1972637T3 (de)
WO (1) WO2008113515A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368764T3 (es) 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.
CN103249742B (zh) * 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
ES2378976B1 (es) * 2010-09-21 2013-05-06 Fundación Centro Nacional De Investigaciones Oncológicas (Cnio) Anticuerpo contra ephrin b2 y su uso.
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
EP2748197A2 (de) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Fc-bispezifische tandem-antikörper
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗C-MET串聯Fc雙特異性抗體
CA3019692A1 (en) * 2016-04-05 2017-10-12 Universitat Stuttgart Monovalent inhibitor of hutnfr1 interaction
GB201617622D0 (en) * 2016-10-18 2016-11-30 VIB VZW and Universiteit Gent Means and methods to treat inflammation
EA202091182A1 (ru) * 2017-11-27 2020-07-29 Балиофарм Аг АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3927828A4 (de) 2019-02-21 2023-02-01 Enosi Life Sciences Corp. Antikörper und enonomere
CN116406381A (zh) * 2020-05-19 2023-07-07 希望之城 工程化抗前列腺干细胞抗原融合蛋白及其用途
WO2022033483A1 (zh) * 2020-08-10 2022-02-17 佧珐药业有限公司 多功能的免疫效应细胞及其应用
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
ES2368764T3 (es) 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.

Also Published As

Publication number Publication date
CN101679520B (zh) 2014-01-15
WO2008113515A2 (en) 2008-09-25
WO2008113515A3 (en) 2008-11-13
JP2010521508A (ja) 2010-06-24
EP1972637A1 (de) 2008-09-24
US8404238B2 (en) 2013-03-26
US20130244341A1 (en) 2013-09-19
US20100150916A1 (en) 2010-06-17
EP2121759A2 (de) 2009-11-25
ES2368764T3 (es) 2011-11-22
JP5534819B2 (ja) 2014-07-02
CA2680085C (en) 2016-05-17
EP1972637B1 (de) 2011-06-29
CA2680085A1 (en) 2008-09-25
CN101679520A (zh) 2010-03-24
US9045535B2 (en) 2015-06-02
PL1972637T3 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
ATE514714T1 (de) Hutnfr1-selektive antagonisten
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
MX2009003093A (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
ATE509953T1 (de) Antikörper gegen den erythropoietinrezeptor und verwendungen davon
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
NO345046B1 (no) Oral doseringsform
LT3339445T (lt) Baltymai, suryšantys interleukiną 13
EA200970810A1 (ru) Модифицированные полипептиды рецептора активина и их применение
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
EP1983002A3 (de) Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2008013948A3 (en) Tyrosine phosphorylation sites
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
WO2008054597A3 (en) Tyrosine phosphorylation sites
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
WO2008013934A8 (en) Tyrosine phosphorylation sites
EP1983003A3 (de) Tyrosinphosphorylationsstellen und spezifische Antikörper
DE602005019416D1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
WO2010040736A3 (en) Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
WO2008036337A8 (en) Predicted phosphorylation sites

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1972637

Country of ref document: EP